A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
PET based tools can improve the early diagnosis of Alzheimer’s disease (AD) and differential diagnosis of dementia. The importance of identifying individuals at risk of developing dementia among people with subjective cognitive complaints or mild cognitive impairment has clinical, social, and therapeutic implications. Within the two major classes of AD biomarkers currently identified, that is, markers of pathology and neurodegeneration, amyloid- and FDG-PET imaging represent decisive tools for their measurement. As a consequence, the PET tools have been recognized to be of crucial value in the recent guidelines for the early diagnosis of AD and other dementia conditions. The references based recommendations, however, include large PET imaging literature based on visual methods that greatly reduces sensitivity and specificity and lacks a clear cut-off between normal and pathological findings. PET imaging can be assessed using parametric or voxel-wise analyses by comparing the subject’s scan with a normative data set, significantly increasing the diagnostic accuracy. This paper is a survey of the relevant literature on FDG and amyloid-PET imaging aimed at providing the value of quantification for the early and differential diagnosis of AD. This allowed a meta-analysis and GRADE analysis revealing high values for PET imaging that might be useful in considering recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 2×
“The basic concept is that FDG-PET estimates glucose consumption at the synaptic-astrocyte level [90] thus picking-up very early changes already detectable even in asymptomatic subjects at high risk for AD [113, 114].”
BackgroundGRADE guidelines: 7. Rating the quality of evidence—inconsistency
Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Glasziou, P., Jaeschke, R., Akl, E. A., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.03.017 · Cited by 2,320
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 4×
“In fact, both the “Dubois” [5, 9] and the NIA-AA [6, 8] new diagnostic criteria have included FDG-PET as a valid tool for biomarker measure of neurodegeneration, by showing specific metabolic changes that precede atrophy as detected with MRI.”
BackgroundMethodInfluentialSelf-citationGrading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 1×
“A paper from Mintun and colleagues [126] focused on this aspect by using”
Method(1995) · PubMed Central · doi:10.2967/jnumed.120.252510a · Cited by 996
Research works printed but not linked: 98
- 10.1212/01.wnl.0000269790.05105.16 · DOI · Paper page
- 10.1002/mds.23291 · DOI · Paper page
- 10.1111/j.1749-6632.2011.06015.x · DOI · Paper page
- 10.1111/j.1749-6632.2011.06025.x · DOI
- 10.1016/j.jalz.2011.03.008 · DOI · Paper page
- 10.1016/j.jalz.2011.03.005 · DOI · Paper page
- 10.1016/j.jalz.2011.03.003 · DOI · Paper page
- 10.1016/S1474-4422(07)70178-3 · DOI · Paper page
- 2001, Journal of the American Medical Association, 286, 2120, 10.1001/jama.286.17.2120 · DOI · Paper page
- 10.1007/s12035-008-8019-y · DOI
- 10.2967/jnumed.111.089730 · DOI · Paper page
- 10.1006/nimg.1998.0381 · DOI · Paper page
- 1995, Journal of Nuclear Medicine, 36, 1238
- 10.2967/jnumed.111.094946 · DOI · Paper page
- 10.2967/jnumed.111.096578 · DOI · Paper page
- 10.1001/archneur.62.11.1728 · DOI · Paper page
- 10.3174/ajnr.A1357 · DOI · Paper page
- 10.1212/WNL.0b013e3181b23564 · DOI · Paper page
- 10.1016/j.jalz.2010.06.004 · DOI · Paper page
- 10.2967/jnumed.106.037762 · DOI · Paper page
- 10.1016/j.neuroimage.2013.01.015 · DOI · Paper page
- 10.1016/j.neuroimage.2009.06.079 · DOI
- 10.1007/s00259-011-2021-8 · DOI · Paper page
- 10.1001/archneurol.2008.511 · DOI · Paper page
- 10.1212/WNL.0b013e318246d67a · DOI · Paper page
- 2012, The New England Journal of Medicine, 367
- 10.4061/2011/946590 · DOI
- 1983, Journal of Cerebral Blood Flow and Metabolism, 3, 391, 10.1038/jcbfm.1983.57 · DOI · Paper page
- 1984, Radiology, 150, 625, 10.1148/radiology.150.3.6607481 · DOI
- 10.1007/s00259-005-1762-7 · DOI · Paper page
- 10.1007/s00259-009-1218-6 · DOI
- 10.1148/radiol.12120010 · DOI · Paper page
- 10.1016/j.neuroimage.2010.10.081 · DOI · Paper page
- 10.1016/S1474-4422(09)70299-6 · DOI · Paper page
- 10.3174/ajnr.A1809 · DOI · Paper page
- 10.1002/path.2885 · DOI · Paper page
- 10.2967/jnumed.110.076315 · DOI · Paper page
- 10.1016/S0960-894X(01)00734-X · DOI · Paper page
- 10.1002/ana.20009 · DOI · Paper page
- 10.2967/jnumed.108.058529 · DOI · Paper page
- 10.1177/0891988710363715 · DOI · Paper page
- 10.2967/jnumed.110.083683 · DOI
- 10.2967/jnumed.110.082057 · DOI
- 10.1016/j.neurobiolaging.2010.06.015 · DOI
- 10.1002/ana.21345 · DOI · Paper page
- 10.1016/j.neurobiolaging.2007.03.029 · DOI · Paper page
- 2005, Journal of Nuclear Medicine, 46, 1959
- 10.1016/j.neuroimage.2010.12.070 · DOI · Paper page
- 10.2967/jnumed.111.095927 · DOI
- 10.1016/j.neuroimage.2012.01.099 · DOI · Paper page
- 10.1053/j.semnuclmed.2011.02.005 · DOI
- 10.1016/S1474-4422(11)70123-5 · DOI · Paper page
- 10.1001/archneurol.2011.150 · DOI · Paper page
- 10.2967/jnumed.112.109009 · DOI · Paper page
- 10.2967/jnumed.111.090340 · DOI · Paper page
- 10.1186/1748-5908-6-62 · DOI · Paper page
- 2011, Chinese Journal of Evidence-Based Medicine, 11, 1444
- 10.1016/S1474-4422(12)70305-8 · DOI
- 2004, Neurology, 63, 2332, 10.1212/01.WNL.0000147469.18313.3B · DOI · Paper page
- 1988, Journal of Consulting and Clinical Psychology, 56, 123, 10.1037/0022-006X.56.1.123 · DOI · Paper page
- 2005, Journal of Nuclear Medicine, 46, 1625
- 10.1007/s00259-004-1576-z · DOI
- 10.1159/000241879 · DOI · Paper page
- 10.1007/s00259-013-2478-8 · DOI
- 10.1007/s00259-013-2458-z · DOI
- 10.1016/j.expneurol.2004.06.017 · DOI
- 10.1016/S0006-8993(00)02945-0 · DOI · Paper page
- 10.1038/nrneurol.2012.81 · DOI
- 10.1016/S1474-4422(08)70001-2 · DOI · Paper page
- 10.1002/ana.22068 · DOI · Paper page
- 10.1016/S1474-4422(11)70077-1 · DOI · Paper page
- 10.1007/s00259-011-1821-1 · DOI
- 10.1007/s00259-012-2088-x · DOI · Paper page
- 10.2967/jnumed.112.107185 · DOI
- 10.2174/156720510790274446 · DOI · Paper page
- 10.1002/ana.21598 · DOI · Paper page
- 10.1016/j.bbadis.2011.11.006 · DOI
- 10.1159/000318754 · DOI
- 10.1016/j.jns.2009.06.005 · DOI
- 10.1016/j.jalz.2010.03.003 · DOI · Paper page
- 10.1212/WNL.78.1_MeetingAbstracts.P03.106 · doi:10.1212/wnl.78.1_meetingabstracts.p03.106
- 10.1136/jnnp.74.10.1371 · DOI · Paper page
- 10.1073/pnas.0500579102 · DOI · Paper page
- 2005, Journal of Nuclear Medicine, 46, 233
- 10.1016/S1053-8119(03)00346-X · DOI
- 10.1016/j.bandl.2004.11.007 · DOI
- 1999, Archives of Neurology, 56, 303, 10.1001/archneur.56.3.303 · DOI · Paper page
- 2001, Archives of Neurology, 58, 1985, 10.1001/archneur.58.12.1985 · DOI · Paper page
- 10.1002/mds.22581 · DOI · Paper page
- 10.3233/JAD-2011-0020 · DOI
- 10.1093/brain/awl178 · DOI · Paper page
- 10.1093/brain/aws125 · DOI · Paper page
- 2012, The Lancet Neurology, 11, 1057, 10.1016/S1474-4422(12)70227-2 · DOI · Paper page
- 2013, The Lancet Neurology, 12, 357, 10.1016/S1474-4422(13)70044-9 · DOI · Paper page
- 10.1002/ana.10161 · DOI · Paper page
- 10.1212/WNL.0b013e318232ac1a · DOI · Paper page
- 10.1007/s12149-009-0330-9 · DOI
- 10.1016/j.jalz.2013.06.001 · DOI · Paper page
Cited by
Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery
Patching, S. G. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9672-6 · Cited by 361
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226
Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria
Caminiti, S. P., Sala, A., Iaccarino, L., Beretta, L., Pilotto, A., Gianolli, L., Iannaccone, S., Magnani, G., Padovani, A., Ferini-Strambi, L., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0473-4 · Cited by 86
Self-citationUnified theory of Alzheimer’s disease (UTAD): implications for prevention and curative therapy
Nehls, M. (2016) · Journal of Molecular Psychiatry · doi:10.1186/s40303-016-0018-8 · Cited by 41
Ito, K., Sasaki, M., Takahashi, J., Uwano, I., Yamashita, F., Higuchi, S., Goodwin, J., Harada, T., Kudo, K., & Terayama, Y. (2015) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2015.01.020 · Cited by 26
Metadata
- Authors
- Daniela, P., Orazio, S., Alessandro, P., Mariano, N. F., Leonardo, I., Pasquale Anthony, D. R., Giovanni, F., & Carlo, C.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-22
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W1993217119
- Cited by
- 58
- References
- 38
- FWCI
- 5.61
- Type
- journal article
- Language
- en
- Update notices
- erratum (2014-06-11)
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.